



Eurofins expands its Canadian Testing offering with the acquisition of EnvironeX

31 October 2018

The EnvironeX Group will strengthen Eurofins' position in the Canadian Environmental and AgriFood Testing Markets

Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, announces that it has acquired EnvironeX Group Inc. (EnvironeX), from Marc Hamilton and Persistence Capital Partners (PCP).

Founded in 2005 by Marc Hamilton and supported by PCP since 2015, EnvironeX is a leading provider of Testing services to the Environment, AgriFood and Health & Pharmaceuticals sectors in Quebec, Canada. EnvironeX operates three laboratories and one service point, employs 275 staff and is expected to generate ca. CAD30m of revenues in 2018. EnvironeX has grown steadily over the last decade, servicing a broad customer base, including industrial clients, municipalities, engineering firms and environmental consultants in sectors such as Agrifood, Agriculture, Health and Pharmaceuticals.

EnvironeX will complement Eurofins Food and Environment Testing footprint in Canada, which employs over 200 staff and operates four laboratories and three service centres. The additional staff, locations, coverage and technical expertise is in line with the Group's commitment to providing its clients a world class level of service in all main countries where they operate.

Comment from **Dr. Gilles Martin**, Eurofins CEO: "We are very pleased to welcome EnvironeX to the Eurofins Group. EnvironeX is a perfect fit for Eurofins and will provide an excellent platform for growth in Canada as we share the same entrepreneurial values and a strong desire to utilize service excellence, quality, innovation and technology as significant pillars of our growth".

Comment from **Marc Hamilton**, EnvironeX CEO: "Today is an important step for EnvironeX. We are pleased and proud to benefit from Eurofins' expertise to continue to grow in the Canadian market. I am personally excited to join our forces and competencies with the Eurofins team and provide our customers with diversified and high quality analytical services".

For more information, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is a scientific leader in food, environment and pharmaceutical products testing and in agrosience CRO services. It is also one of the independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 40,000 staff in more than 650 laboratories across 45 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.